Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients

CardioVascular and Interventional Radiology

Volumn 36, Issue 1, 2013, Pages 158-165

  Klingenstein, A ^a   Haug, A R ^a   Zech, C J ^a   Schaller, U C ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b KLINIKUM AUGSBURG   (Germany)

Author keywords

90Y microspheres; Hepatic metastases; Radioembolization; Uveal melanoma

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CISPLATIN; DACARBAZINE; FLUORODEOXYGLUCOSE; MICROSPHERE; RESIN; STEROID; YTTRIUM 90;

ACUTE TOXICITY; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HEPATIC ARTERY; HEPATOMEGALY; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LIVER METASTASIS; MALE; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT SAFETY; PREDICTION; PRIORITY JOURNAL; RADIOEMBOLIZATION; RETROSPECTIVE STUDY; SALVAGE THERAPY; STOMACH ULCER; SURVIVAL TIME; TREATMENT RESPONSE; UVEA MELANOMA; WHOLE BODY CT; WHOLE BODY PET;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE-FREE SURVIVAL; EMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SALVAGE THERAPY; SEX FACTORS; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UVEAL NEOPLASMS; YTTRIUM RADIOISOTOPES;

EID: 84872686775     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-012-0373-5     Document Type: Article

References (35)

1. Damato B (2004) Developments in the management of uveal melanoma. Clin Exp Ophthalmol 32(6):639-667
2. Peters S, Voelter V, Zografos L et al (2006) Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol 17:578-583
3. Haritoglou I, Wolf A, Maier T et al (2009) Osteopontin and "melanoma inhibitory activity": comparison of two serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica 223(4):239-243
4. Schuster R, Lindner M, Wacker F et al (2010) Transarterial chemoembolization of liver metastases from uveal melanoma after failure of systemic therapy: toxicity and outcome. Melanoma Res 20(3):191-196
5. Kivelä T, Eskelin S, Kujala E (2006) Metastatic uveal melanoma. Int Ophthalmol Clin 46:133-149
6. Schmittel A, Scheulen ME, Bechrakis NE et al (2005) Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Res 15:205-207
7. 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J Surg 76:696-703
8. ® in patients with nonresectable liver tumors. Cancer Biother Radiopharm 20(2):200-208
9. Jakobs TF, Hoffmann RT, Tatsch K et al (2008) Therapieresponse von Lebertumoren nach selektiver interner Radiotherapie. Radiologe 48:839-849
10. Kucuk ON, Soydal C, Laci S et al (2011) Selective intraarterial radionuclide therapy with yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors. World J Surg Oncol 9:86
11. Ho S, Lau WY, Leung TW et al (1997) Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 24:293-298
12. Gray B, van Hazel G, Buck M et al (2000) Treatment of colorectal liver metastases with SIR-spheres plus chemotherapy. GI Cancer 3:249-257
13. 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg 5:294-302
14. Lewandowski RJ, Sato KT, Atassi B et al (2007) Radioembolization with (90)y microspheres: angiographic and technical considerations. Cardiovasc Interv Radiol 30(4):571-592
15. Salem R, Thurston KG (2006) Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies: Part 1: technical and methodologic considerations. J Vasc Interv Radiol 17(8):1251-1278
16. Salem R, Lewandowski RJ, Gates VL et al (2011) Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol 22(3):265-278
17. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
18. 90Y microspheres. Eur J Nucl Med Mol Imaging 28:1037-1045
19. Barak V, Frenkel S, Kalickman I et al (2007) Serum markers to detect metastatic uveal melanoma. Anticancer Res 27:1897-1900
20. Vente MA, Wondergem M, van der Tweel I et al (2009) Yttrium-90 microsphere SIRT for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 19(4):951-959
21. Cosimelli M, Golfieri R, Cagol PP et al (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103(3):324-331
22. Kennedy A, Nutting C, Jakobs T et al (2009) A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Investig 27:682-690
23. Farrag A, Ceulemans G, Voordeckers M et al (2010) Can 18F-FDG-PET response during radiotherapy be used as a predictive factor for the outcome of head and neck cancer patients? Nucl Med Commun 31:495-501
24. Higashi T, Hatano E, Ikai I et al (2010) FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 37:468-482
25. Bienert M, McCook B, Carr BI et al (2005) 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging 32(7):778-787
26. Szyszko T, Al-Nahhas A, Tait P et al (2007) Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres. Nucl Med Commun 28(1):21-24
27. Jiao LR, Szyszko T, Al-Nahhas A et al (2007) Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. Eur J Surg Oncol 33:597-602
28. Haug AR, Schmidt GP, Klingenstein A et al (2007) F-18-fluoro-2- deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers. J Comput Assist Tomogr 31(4):629-634
29. Klingenstein A, Haug AR, Nentwich MM et al (2010) Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma. Melanoma Res 20(6):511-516
30. Miller FH, Keppke AL, Reddy D et al (2007) Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. Am J Roentgenol 188(3):776-783
31. Wong CY, Qing F, Savin M et al (2005) Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 SIRT as evaluated by 18F fluorodeoxyglucose positron emission tomographic imaging. J Vasc Interv Radiol 16(8):1101-1106
32. Wang SC, Bester L, Burnes JP et al (2010) Clinical care and technical recommendations for 90yttrium microsphere treatment of liver cancer. J Med Imaging Radiat Oncol 54(3):178-187
33. 90yttrium microspheres. Dig Dis Sci 53:2556-2563
34. 90Y-resin microspheres in metastatic breast cancer patients: findings and clinical significance. Cardiovasc Interv Radiol 34:964-972
35. Van Hazel G, Blackwell A, Anderson J et al (2004) Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88(2):78